Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-105 SAD and MAD Study in Healthy Adults
NCT07869654Phase 1Not yet recruiting
- Sponsor
- Adjuvia Therapeutics
- Start
- Oct 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATI-105 in Friedreich ataxia (FA), sponsored by Adjuvia Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ATI-105
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT07869654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869654.